1. Home
  2. GLED vs MXCT Comparison

GLED vs MXCT Comparison

Compare GLED & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GLED

GalaxyEdge Acquisition Corporation Ordinary Shares

N/A

Current Price

$10.10

Market Cap

160.8M

Sector

Finance

ML Signal

N/A

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

SELL

Current Price

$1.45

Market Cap

136.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GLED
MXCT
Founded
2025
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
160.8M
136.2M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
GLED
MXCT
Price
$10.10
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $4.11
AVG Volume (30 Days)
110.0K
★ 1.1M
Earning Date
N/A
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$15.53
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.93
$0.64
52 Week High
$10.09
$1.81

Technical Indicators

Market Signals
Indicator
GLED
MXCT
Relative Strength Index (RSI) 74.48 69.59
Support Level $9.97 $1.15
Resistance Level N/A $1.54
Average True Range (ATR) 0.01 0.07
MACD 0.00 0.05
Stochastic Oscillator 100.00 85.69

Price Performance

Historical Comparison
GLED
MXCT

About GLED GalaxyEdge Acquisition Corporation Ordinary Shares

GalaxyEdge Acquisition Corp is a newly organized blank check company. The company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: